...
首页> 外文期刊>BMC Pediatrics >Intravenous versus intravenous/oral antibiotics for perforated appendicitis in pediatric patients: a systematic review and meta-analysis
【24h】

Intravenous versus intravenous/oral antibiotics for perforated appendicitis in pediatric patients: a systematic review and meta-analysis

机译:儿科患者穿孔阑尾炎的静脉内与静脉内/口服抗生素:系统审查和荟萃分析

获取原文
           

摘要

BACKGROUND:The use of oral (PO) antibiotics following a course of certain intravenous (IV) antibiotics is proposed in order to avoid the complications of IV medications and to decrease the cost. However, the efficacy and safety of sequential IV/PO antibiotics is unclear and requires further study.METHODS:The databases, including PubMed, EMBASE and Cochrane Library, were searched. Studies comparing outcomes in patients with perforated appendicitis receiving sequential IV/PO and PO antibiotics therapy were screened. The Newcastle-Ottawa Scale (NOS) and the Jadad score were used to evaluate the quality of the cohort and the randomized controlled portions of the trial, respectively. Statistical heterogeneity was assessed using the I2 value. A fixed or random-effect model was applied according to the I2 value.RESULTS:Five controlled studies including a total of 580 patients were evaluated. The pooled estimates revealed that sequential IV/PO antibiotic therapy did not increase the risk of complications, with a risk ratio (RR) of 0.97 (95% CI 0.51-1.83, P?=?0.93) for postoperative abscess, 1.04 (95% CI 0.25-4.36, P?=?0.96) for wound infection and 0.62 (95% CI 0.33-1.16, P?=?0.13) for readmission.CONCLUSIONS:Our study demonstrates that sequential IV/PO antibiotic therapy is noninferior to IV antibiotic therapy regarding postoperative abscess, wound infection and readmission.
机译:背景:提出了在某些静脉内(IV)抗生素过程中使用口腔(PO)抗生素,以避免IV药物的并发症并降低成本。然而,序贯IV / PO抗生素的功效和安全性尚不清楚,需要进一步研究。审查:包括PubMed,Embase和Cochrane图书馆的数据库。筛选筛选序列IV / PO和PO抗生素治疗的穿孔阑尾炎患者结果的研究。纽卡斯尔 - 渥太华规模(NOS)和JADAD分别用于评估队列的质量和试验的随机控制部分。使用I2值评估统计异质性。根据I2值施用固定或随机效应模型。结果:5项受控研究,包括共580例患者。汇总的估计表明,序贯IV / PO抗生素治疗没有增加并发症的风险,风险比(RR)为0.97(95%CI 0.51-1.83,P?= 0.93),1.04(95%) CI 0.25-4.36,p?= 0.96)用于伤口感染,0.62(95%CI 0.33-1.6,p?= 0.13)用于阅约度:我们的研究表明,序贯IV / PO抗生素治疗是非抗生素的抗生素治疗治疗关于术后脓肿,伤口感染和入伍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号